Selective inhibition of C-domain ACE (cACE) has the advantage of reducing angiotensin II production, a potent vasoconstrictor implicated in hypertension while preserving N-domain ACE (nACE) activity involved in bradykinin degradation, leading to increased vasodilatory effects and lower blood pressure. The gene discussed is ACE; the disease is hypertensive disorder.